NasdaqGM:XNCR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Xencor's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XNCR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: XNCR's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

4.3%

XNCR

3.8%

US Biotechs

2.8%

US Market


1 Year Return

8.5%

XNCR

24.5%

US Biotechs

20.9%

US Market

Return vs Industry: XNCR underperformed the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: XNCR underperformed the US Market which returned 20.7% over the past year.


Shareholder returns

XNCRIndustryMarket
7 Day4.3%3.8%2.8%
30 Day9.1%12.2%11.1%
90 Day22.2%10.1%6.5%
1 Year8.5%8.5%26.6%24.5%23.6%20.9%
3 Year98.9%98.9%24.2%17.8%47.3%37.6%
5 Year193.0%193.0%13.7%5.9%94.3%72.9%

Long-Term Price Volatility Vs. Market

How volatile is Xencor's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xencor undervalued compared to its fair value and its price relative to the market?

4.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: XNCR ($42.75) is trading above our estimate of fair value ($18.18)

Significantly Below Fair Value: XNCR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: XNCR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: XNCR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XNCR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XNCR is overvalued based on its PB Ratio (4.3x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Xencor forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

12.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XNCR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XNCR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XNCR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XNCR's revenue (41.7% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: XNCR's revenue (41.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XNCR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Xencor performed over the past 5 years?

-18.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XNCR is currently unprofitable.

Growing Profit Margin: XNCR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XNCR is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.

Accelerating Growth: Unable to compare XNCR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XNCR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: XNCR has a negative Return on Equity (-14.52%), as it is currently unprofitable.


Next Steps

Financial Health

How is Xencor's financial position?


Financial Position Analysis

Short Term Liabilities: XNCR's short term assets ($570.9M) exceed its short term liabilities ($70.5M).

Long Term Liabilities: XNCR's short term assets ($570.9M) exceed its long term liabilities ($7.4M).


Debt to Equity History and Analysis

Debt Level: XNCR is debt free.

Reducing Debt: XNCR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XNCR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XNCR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Xencor current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XNCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XNCR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XNCR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XNCR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XNCR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Bassil Dahiyat (50 yo)

15.75yrs

Tenure

US$3,731,514

Compensation

Dr. Bassil I. Dahiyat, Ph.D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. He serves as Chairman at Xencor Inc. Dr. Dahiyat served as C...


CEO Compensation Analysis

Compensation vs Market: Bassil's total compensation ($USD3.73M) is about average for companies of similar size in the US market ($USD5.14M).

Compensation vs Earnings: Bassil's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Bassil Dahiyat
Co-Founder15.75yrsUS$3.73m0.21%
$ 5.1m
John Kuch
Senior VP & CFO10.08yrsUS$1.58m0.14%
$ 3.5m
John Desjarlais
Senior VP of Research & Chief Scientific Officer6.33yrsUS$1.89m0.15%
$ 3.6m
Celia Eckert
VP, General Counsel & Corporate Secretary1.17yrsUS$2.27mno data
Allen Yang
Senior VP & Chief Medical Officer0.92yrUS$2.73mno data
Charles Liles
Associate Director and Head of Corporate Communications & Investor Relationsno datano datano data
Julie Casciani
Executive Director of Human Resources0.83yrno datano data

3.8yrs

Average Tenure

52yo

Average Age

Experienced Management: XNCR's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Bassil Dahiyat
Co-Founder15.75yrsUS$3.73m0.21%
$ 5.1m
Richard Ranieri
Independent Director2.92yrsUS$294.30k0%
$ 0
Richard Lerner
Member of Scientific Advisory Boardno datano datano data
Alan Montgomery
Independent Director5.67yrsUS$333.79k0%
$ 0
Yujiro Hata
Independent Director5.33yrsUS$294.63k0%
$ 0
Kevin Gorman
Independent Director3.58yrsUS$292.13k0%
$ 0
Jeffrey Ravetch
Member of Scientific Advisory Board11.42yrsno datano data
Ellen Feigal
Independent Director2yrsUS$285.05k0%
$ 0
Kurt Gustafson
Independent Director6.33yrsUS$297.96k0%
$ 0
Dagmar Rosa-Bjorkeson
Independent Director0.92yrUS$306.51kno data

5.3yrs

Average Tenure

64yo

Average Age

Experienced Board: XNCR's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Xencor, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xencor, Inc.
  • Ticker: XNCR
  • Exchange: NasdaqGM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.456b
  • Shares outstanding: 57.46m
  • Website: https://www.xencor.com

Number of Employees


Location

  • Xencor, Inc.
  • 111 West Lemon Avenue
  • Monrovia
  • California
  • 91016
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XNCRNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2013
XE9DB (Deutsche Boerse AG)YesCommon StockDEEURDec 2013

Biography

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening dise...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/28 23:23
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.